Beta Bionics, Inc. beneficial-ownership disclosure: a Soleus-affiliated group led by Guy Levy reports combined holdings of 4,354,501 shares, equal to 9.8% of common stock. The filing attributes 4,323,714 shares to Soleus Capital Management, L.P. and 1,703,961 shares to Soleus Private Equity Fund II, L.P. The percentage bases on 44,561,695 shares outstanding as of April 16, 2026 per the issuer's Form 10-Q cover. Ownership is shown as shared voting and dispositive power through related Soleus entities; declarants disclaim beneficial ownership except for Section 13(d) purposes.
Positive
None.
Negative
None.
Insights
Soleus group holds a near-10% stake via pooled vehicles; voting and disposition are shared across related entities.
The filing lists 4,354,501 shares (9.8%) tied to Guy Levy and affiliated Soleus entities, with shared voting/dispositive power across funds and manager entities. This structure is typical for investment managers consolidating economic exposure through funds.
Key dependencies include whether these holdings are passive under Schedule 13G rules and any future Section 13(d) obligations. Subsequent filings would show changes in voting position or transfers.
This amendment clarifies ownership counts and the outstanding-share basis; it does not announce transactions or changes in control.
The filing ties percentage calculations to the Form 10-Q cover’s 44,561,695 shares outstanding as of April 16, 2026. It lists per-entity counts such as 1,703,961 and 2,619,753, useful for tracking which legal entities hold economic exposure.
Watch for future amendments that would report purchases, dispositions, or a shift to Schedule 13D if intent to influence governance changes.
Key Figures
Outstanding shares used for calculation:44,561,695 sharesTotal reported shares (Guy Levy / group):4,354,501 sharesSoleus Capital Management holdings:4,323,714 shares+3 more
6 metrics
Outstanding shares used for calculation44,561,695 sharesas of April 16, 2026 (Form 10-Q cover)
Total reported shares (Guy Levy / group)4,354,501 sharescombined reported holdings attributed to Guy Levy and affiliates
Soleus Capital Management holdings4,323,714 sharesheld directly by Soleus Capital Management, L.P.
Soleus Private Equity Fund II holdings1,703,961 sharesheld directly by Soleus Private Equity Fund II, L.P.
Soleus Capital Master Fund holdings2,619,753 sharesheld directly by Soleus Capital Master Fund, L.P.
Reported ownership percentage (Guy Levy)9.8%percent of class reported for Guy Levy
Key Terms
Schedule 13G/A, shared dispositive power, Form 10-Q cover, Section 13(d)
4 terms
Schedule 13G/Aregulatory
"Amendment No. 2 and beneficial ownership disclosure"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
shared dispositive powerfinancial
"Shared Dispositive Power 4,323,714.00 shown in table"
Form 10-Q coverregulatory
"as set forth on the cover of the Issuer's Quarterly Report on Form 10-Q"
Section 13(d)regulatory
"determining their obligations under Section 13(d) of the Exchange Act"
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)
Beta Bionics, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
08659B102
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
08659B102
1
Names of Reporting Persons
Soleus Private Equity Fund II, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,703,961.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,703,961.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,703,961.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.8 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: (1) The shares reported in the table above are held directly by Soleus Private Equity Fund II, L.P. ("Soleus PE"). Soleus Private Equity GP II, LLC ("Soleus PE GP") is the sole general partner of Soleus PE, Soleus PE GP II, LLC is the sole manager of Soleus PE GP, Soleus Capital Management, L.P. ("SCM ") is the investment manager for Soleus PE and for Soleus Capital Master Fund, L.P. ("Master Fund"), and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP II, LLC and of Soleus GP, LLC. Each of Mr. Levy, Soleus PE GP II, LLC, Soleus PE GP, SCM and Soleus GP, LLC disclaims beneficial ownership of these shares held by Soleus PE other than for the purpose of determining their obligations under Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose.
(2) The percentage listed in row 11 is calculated based upon 44,561,695 shares of the common stock of Beta Bionics, Inc. (the "Issuer") outstanding as of April 16, 2026, as set forth on the cover of the Issuer's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 that was filed with the Securities and Exchange Commission on April 21, 2026 (the "Form 10-Q").
SCHEDULE 13G
CUSIP Number(s):
08659B102
1
Names of Reporting Persons
Soleus Private Equity GP II, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,703,961.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,703,961.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,703,961.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.8 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: (1) The shares reported in the table above are held directly by Soleus PE. Soleus PE GP is the sole general partner of Soleus PE, Soleus PE GP II, LLC is the sole manager of Soleus PE GP, SCM is the investment manager for Soleus PE and for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP II, LLC and of Soleus GP, LLC. Each of Mr. Levy, Soleus PE GP II, LLC, Soleus PE GP, SCM and Soleus GP, LLC disclaims beneficial ownership of these shares held by Soleus PE other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose.
(2) The percentage listed in row 11 is calculated based upon 44,561,695 shares of common stock of the Issuer outstanding as of April 16, 2026, as set forth on the cover of the Form 10-Q.
SCHEDULE 13G
CUSIP Number(s):
08659B102
1
Names of Reporting Persons
Soleus PE GP II, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,703,961.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,703,961.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,703,961.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.8 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: (1) The shares reported in the table above are held directly by Soleus PE. Soleus PE GP is the sole general partner of Soleus PE, Soleus PE GP II, LLC is the sole manager of Soleus PE GP, SCM is the investment manager for Soleus PE and for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP II, LLC and of Soleus GP, LLC. Each of Mr. Levy, Soleus PE GP II, LLC, Soleus PE GP, SCM and Soleus GP, LLC disclaims beneficial ownership of these shares held by Soleus PE other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose.
(2) The percentage listed in row 11 is calculated based upon 44,561,695 shares of common stock of the Issuer outstanding as of April 16, 2026, as set forth on the cover of the Form 10-Q.
SCHEDULE 13G
CUSIP Number(s):
08659B102
1
Names of Reporting Persons
Soleus Capital Master Fund, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,619,753.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,619,753.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,619,753.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.9 %
12
Type of Reporting Person (See Instructions)
FI
Comment for Type of Reporting Person: (1) The shares reported in the table above are held directly by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund, Soleus Capital Group, LLC ("SCG") is the sole managing member of Soleus Capital, LLC, SCM is the investment manager for Soleus PE and for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of SCG and of Soleus GP, LLC. Each of SCG, Soleus Capital, LLC, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose.
(2) The percentage listed in row 11 is calculated based upon 44,561,695 shares of common stock of the Issuer outstanding as of April 16, 2026, as set forth on the cover of the Form 10-Q.
SCHEDULE 13G
CUSIP Number(s):
08659B102
1
Names of Reporting Persons
Soleus Capital, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,619,753.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,619,753.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,619,753.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.9 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: (1) The shares reported in the table above are held directly by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, LLC, SCM is the investment manager for Soleus PE and for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of SCG and of Soleus GP, LLC. Each of SCG, Soleus Capital, LLC, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose.
(2) The percentage listed in row 11 is calculated based upon 44,561,695 shares of common stock of the Issuer outstanding as of April 16, 2026, as set forth on the cover of the Form 10-Q.
SCHEDULE 13G
CUSIP Number(s):
08659B102
1
Names of Reporting Persons
Soleus Capital Group, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,619,753.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,619,753.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,619,753.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.9 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: (1) The shares reported in the table above are held directly by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, LLC, SCM is the investment manager for Soleus PE and for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of SCG and of Soleus GP, LLC. Each of SCG, Soleus Capital, LLC, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose.
(2) The percentage listed in row 11 is calculated based upon 44,561,695 shares of common stock of the Issuer outstanding as of April 16, 2026, as set forth on the cover of the Form 10-Q.
SCHEDULE 13G
CUSIP Number(s):
08659B102
1
Names of Reporting Persons
Soleus Capital Management, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,323,714.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,323,714.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,323,714.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.7 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: (1) The shares reported in the table above are held directly by Soleus PE and by Master Fund. Soleus PE GP is the sole general partner of Soleus PE, Soleus PE GP II, LLC is the sole manager of Soleus PE GP, SCM is the investment manager for Soleus PE, and Soleus GP, LLC is the sole general partner of SCM. Soleus Capital, LLC is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, LLC, SCM is the investment manager for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP II, LLC, SCG and Soleus GP, LLC. Each of Soleus PE GP, Soleus PE GP II, LLC, Soleus Capital, LLC, SCG, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held directly by Soleus PE and Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose.
(2) The percentage listed in row 11 is calculated based upon 44,561,695 shares of common stock of the Issuer outstanding as of April 16, 2026, as set forth on the cover of the Form 10-Q.
SCHEDULE 13G
CUSIP Number(s):
08659B102
1
Names of Reporting Persons
Soleus GP, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,323,714.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,323,714.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,323,714.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.7 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: (1) The shares reported in the table above are held directly by Soleus PE and by Master Fund. Soleus PE GP is the sole general partner of Soleus PE, Soleus PE GP II, LLC is the sole manager of Soleus PE GP, SCM is the investment manager for Soleus PE, and Soleus GP, LLC is the sole general partner of SCM. Soleus Capital, LLC is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, LLC, SCM is the investment manager for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP II, LLC, SCG and Soleus GP, LLC. Each of Soleus PE GP, Soleus PE GP II, LLC, Soleus Capital, LLC, SCG, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held directly by Soleus PE and Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose.
(2) The percentage listed in row 11 is calculated based upon 44,561,695 shares of common stock of the Issuer outstanding as of April 16, 2026, as set forth on the cover of the Form 10-Q.
SCHEDULE 13G
CUSIP Number(s):
08659B102
1
Names of Reporting Persons
Levy Guy
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
30,787.00
6
Shared Voting Power
4,323,714.00
7
Sole Dispositive Power
30,787.00
8
Shared Dispositive Power
4,323,714.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,354,501.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.8 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: (1) The shares reported in the table above are held directly by Soleus PE and by Master Fund. Soleus PE GP is the sole general partner of Soleus PE, Soleus PE GP II, LLC is the sole manager of Soleus PE GP, SCM is the investment manager for Soleus PE, and Soleus GP, LLC is the sole general partner of SCM. Soleus Capital, LLC is the sole general partner of Master Fund, SCG is the sole managing member of Soleus Capital, LLC, SCM is the investment manager for Master Fund, and Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP II, LLC, SCG and Soleus GP, LLC. Each of Soleus PE GP, Soleus PE GP II, LLC, Soleus Capital, LLC, SCG, SCM, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held directly by Soleus PE and Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such shares for any other purpose.
(2) The percentage listed in row 11 is calculated based upon 44,561,695 shares of common stock of the Issuer outstanding as of April 16, 2026, as set forth on the cover of the Form 10-Q.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Beta Bionics, Inc.
(b)
Address of issuer's principal executive offices:
11 Hughes, Irvine, California 92618
Item 2.
(a)
Name of person filing:
The information in rows 5 through 9 and 11 on the cover pages to this Schedule 13G,
including the footnotes thereto, which reflects beneficial ownership of the Common
Stock of the Issuer as of Mach 31, 2026, is hereby incorporated by reference.
Soleus Private Equity Fund II, L.P. - 1,703,961
Soleus Private Equity GP II, LLC - 1,703,961
Soleus PE GP II, LLC - 1,703,961
Soleus Capital Master Fund, L.P. - 2,619,753
Soleus Capital, LLC - 2,619,753
Soleus Capital Group, LLC - 2,619,753
Soleus Capital Management, L.P. - 4,323,714
Soleus GP, LLC - 4,323,714
Guy Levy - 4,354,501
(b)
Address or principal business office or, if none, residence:
Soleus Private Equity Fund II, L.P. 100 Field Point Road, Suite 200 Greenwich, CT 06830
Soleus Private Equity GP II, LLC 100 Field Point Road, Suite 200 Greenwich, CT 06830
Soleus PE GP II, LLC 100 Field Point Road, Suite 200 Greenwich, CT 06830
Soleus Capital Master Fund, L.P. 100 Field Point Road, Suite 200 Greenwich, CT 06830
Soleus Capital, LLC 100 Field Point Road, Suite 200 Greenwich, CT 06830
Soleus Capital Group, LLC 100 Field Point Road, Suite 200 Greenwich, CT 06830
Soleus Capital Management, L.P. 100 Field Point Road, Suite 200 Greenwich, CT 06830
Soleus GP, LLC 100 Field Point Road, Suite 200 Greenwich, CT 06830
Guy Levy c/o Soleus Capital Management, L.P. 100 Field Point Road, Suite 200 Greenwich, CT 06830
(c)
Citizenship:
Soleus Private Equity Fund II, L.P. - Delaware
Soleus Private Equity GP II, LLC - Delaware
Soleus PE GP II, LLC - Delaware
Soleus Capital Master Fund, L.P. - Cayman Islands
Soleus Capital, LLC - Delaware
Soleus Capital Group, LLC - Delaware
Soleus Capital Management, L.P. - Delaware
Soleus GP, LLC - Delaware
Guy Levy - United States
(d)
Title of class of securities:
Common Stock
(e)
CUSIP No.:
08659B102
Item 4.
Ownership
(a)
Amount beneficially owned:
The information in rows 5 through 9 and 11 on the cover pages to this Schedule 13G, including the footnotes thereto, which reflects beneficial ownership of the Common Stock of the Issuer, is hereby incorporated by reference.
Soleus Private Equity Fund II, L.P. - 1,703,961
Soleus Private Equity GP II, LLC - 1,703,961
Soleus PE GP II, LLC - 1,703,961
Soleus Capital Master Fund, L.P. - 2,619,753
Soleus Capital, LLC - 2,619,753
Soleus Capital Group, LLC - 2,619,753
Soleus Capital Management, L.P. - 4,323,714
Soleus GP, LLC - 4,323,714
Guy Levy - 4,354,501
(b)
Percent of class:
Soleus Private Equity Fund II, L.P. - 3.8%
Soleus Private Equity GP II, LLC - 3.8%
Soleus PE GP II, LLC - 3.8%
Soleus Capital Master Fund, L.P. - 5.9%
Soleus Capital, LLC - 5.9%
Soleus Capital Group, LLC - 5.9%
Soleus Capital Management, L.P. - 9.7%
Soleus GP, LLC - 9.7%
Guy Levy - 9.8%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Guy Levy - 30,787
(ii) Shared power to vote or to direct the vote:
Soleus Private Equity Fund II, L.P. - 1,703,961
Soleus Private Equity GP II, LLC - 1,703,961
Soleus PE GP II, LLC - 1,703,961
Soleus Capital Master Fund, L.P. - 2,619,753
Soleus Capital, LLC - 2,619,753
Soleus Capital Group, LLC - 2,619,753
Soleus Capital Management, L.P. - 4,323,714
Soleus GP, LLC - 4,323,714
Guy Levy - 4,323,714
(iii) Sole power to dispose or to direct the disposition of:
Guy Levy - 30-787
(iv) Shared power to dispose or to direct the disposition of:
Soleus Private Equity Fund II, L.P. - 1,703,961
Soleus Private Equity GP II, LLC - 1,703,961
Soleus PE GP II, LLC - 1,703,961
Soleus Capital Master Fund, L.P. - 2,619,753
Soleus Capital, LLC - 2,619,753
Soleus Capital Group, LLC - 2,619,753
Soleus Capital Management, L.P. - 4,323,714
Soleus GP, LLC - 4,323,714
Guy Levy - 4,323,714
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Soleus Private Equity Fund II, L.P.
Signature:
/s/ Guy Levy
Name/Title:
Guy Levy, Managing Member of the Sole Manager of the General Partner of Soleus Private Equity Fund II, L.P.
Date:
05/08/2026
Soleus Private Equity GP II, LLC
Signature:
/s/ Guy Levy
Name/Title:
Guy Levy, Managing Member of the Sole Manager of Soleus Private Equity GP II, LLC
Date:
05/08/2026
Soleus PE GP II, LLC
Signature:
/s/ Guy Levy
Name/Title:
Guy Levy, Managing Member
Date:
05/08/2026
Soleus Capital Master Fund, L.P.
Signature:
/s/ Guy Levy
Name/Title:
Guy Levy, Managing Member of the Managing Member of the General Partner of Soleus Capital Master Fund, L.P.
Date:
05/08/2026
Soleus Capital, LLC
Signature:
/s/ Guy Levy
Name/Title:
Guy Levy, Managing Member of the Managing Member of Soleus Capital, LLC
Date:
05/08/2026
Soleus Capital Group, LLC
Signature:
/s/ Guy Levy
Name/Title:
Guy Levy, Managing Member
Date:
05/08/2026
Soleus Capital Management, L.P.
Signature:
/s/ Guy Levy
Name/Title:
Guy Levy, Managing Member of the General Partner of Soleus Capital Management, L.P.
What stake does Soleus report in Beta Bionics (BBNX)?
The filing reports a combined position of 4,354,501 shares, representing 9.8% of common stock. The percentages are calculated using 44,561,695 shares outstanding as of April 16, 2026, per the issuer's Form 10-Q cover.
Which Soleus entities hold shares of BBNX and how many?
Reported holdings include 1,703,961 shares by Soleus Private Equity Fund II, L.P. and 2,619,753 shares by Soleus Capital Master Fund, L.P., with 4,323,714 shares attributed to Soleus Capital Management, L.P.
Does Guy Levy personally own the reported shares in Beta Bionics?
Guy Levy is shown with total reported holdings of 4,354,501 shares (9.8%) combining direct and shared holdings. Footnotes state certain entities and Mr. Levy disclaim beneficial ownership except for Section 13(d) purposes.
What voting and dispositive powers are reported for these holdings?
The filing shows shared voting power and shared dispositive power over the reported shares across Soleus entities. Guy Levy is listed with small sole voting/dispositive power of 30,787 shares.
What outstanding-share figure is used to calculate the percentages?
Percentages are calculated using 44,561,695 shares outstanding as of April 16, 2026, according to the issuer's Form 10-Q cover cited in the disclosure.
